Reuters logo
1 个月前
BRIEF-RXI Pharma completes enrollment of Phase 1/2 trial with RXI-109
2017年6月21日 / 上午11点12分 / 1 个月前

BRIEF-RXI Pharma completes enrollment of Phase 1/2 trial with RXI-109

1 分钟阅读

June 21 (Reuters) - RXI Pharmaceuticals Corp:

* RXI Pharmaceuticals announces completion of enrollment of Phase 1/2 clinical trial with RXI-109 for retinal scarring

* RXI Pharmaceuticals Corp - RXI-109 has been well tolerated with no drug related issues occurring to date Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below